Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1925316 | 1.00 | HCAR3 (0.52) | HCAR3MAPTALDH1A1LMNAPOLB | |
| SCHEMBL13594578 | 0.85 | ALDH1A1 (0.51) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL4716807 | 0.84 | MAPT (0.67) | HCAR3MAPTALDH1A1LMNAPOLB | |
| SCHEMBL20985280 | 0.83 | HCAR3 (0.64) | HCAR3MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20985278 | 0.83 | HCAR3 (0.64) | HCAR3MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL931990 | 0.82 | HCAR3 (0.64) | HCAR3MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1924879 | 0.82 | ALOX15 (0.55) | MAPTALDH1A1POLBSMN1; SMN2HPGD | |
| SCHEMBL1924881 | 0.82 | ALOX15 (0.55) | MAPTALDH1A1POLBSMN1; SMN2HPGD | |
| SCHEMBL2143238 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1POLBSMN1; SMN2HPGD | |
| SCHEMBL21025998 | 0.80 | ALDH1A1 (0.49) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| EP-1434579-B1 | IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | AMGEN INC (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-7132438-B2 | Benzimidazole derivatives | AMGEN INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20030144286-A1 | Benzimidazole derivatives | TULARIK, INC | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | HCAR3 2265/4885MAPT 1386/4885ALDH1A1 2896/4885 |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | IDO2, IRF2BP2, IRF3 | HCAR3 1607/4885MAPT 2419/4885ALDH1A1 3628/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | HCAR3 2603/4885MAPT 1544/4885ALDH1A1 2211/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | HCAR3 2265/4885MAPT 1386/4885ALDH1A1 2896/4885 |
| US-20030144286-A1 | Benzimidazole derivatives | NFATC1, STAT1, IRF3 | HCAR3 1985/4885MAPT 2784/4885ALDH1A1 1869/4885 |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | NFATC1, STAT1, IRF3 | HCAR3 1985/4885MAPT 2784/4885ALDH1A1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.